Moniyot-131 (Sodium Iodide (131i))

Sodium Iodide-131 is selectively taken up by thyroid cells via the sodium‑iodide symporter. Inside the cells, the isotope emits beta radiation that damages cellular DNA, leading to targeted destruction of thyroid tissue while minimizing impact on surrounding organs.

The prescribed dose of Moniyot-131 is individualized by the treating physician based on factors such as the patient’s thyroid uptake studies, disease severity, body weight, and intended therapeutic goal. No standard dosing regimen is provided publicly.

Safety data are limited; Moniyot-131 may cross the placenta and affect fetal thyroid development, and it can be secreted in breast milk. Use is generally avoided unless the potential benefit justifies the risk, and breastfeeding should be paused during and after treatment as advised by a clinician.

To order Moniyot-131, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moniyot-131 is chemically identical to other Sodium Iodide‑131 preparations but is supplied as an oral solution meeting EU quality standards. Compared with older formulations, it offers comparable efficacy and safety, with the advantage of a controlled manufacturing process and reliable potency.

Moniyot-131 should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from moisture, direct sunlight and physical damage. Handling must follow radiation safety guidelines, including the use of appropriate shielding and protective equipment.

Moniyot-131 is administered orally as a single dose of the prescribed volume of the solution. The patient typically ingests the dose under medical supervision, and post‑administration instructions include hydration, avoiding close contact with pregnant individuals, and monitoring for side effects.

The most serious risks include bone marrow suppression, which can lead to anemia or infection, severe hypothyroidism requiring lifelong hormone replacement, and the rare possibility of radiation‑induced secondary malignancies. Patients should be monitored regularly for blood counts and thyroid function.

Moniyot-131 is contraindicated in patients with known hypersensitivity to iodine or radioactive iodine, those who are pregnant or breastfeeding unless absolutely necessary, and individuals with uncontrolled severe renal impairment that could impede iodine clearance. Clinical judgment is essential for each case.